Description of Invention:
The present invention provides methods of treating inflammatory bowel disease in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B (CT-B). In particular, the present invention provides methods of decreasing the activity of interferon-gamma in a subject, decreasing the activity of IL-12 in a subject, and treating or preventing a Th1 T-cell mediated autoimmune disorder.

Inventors:
Warren Strober (NIAID)
Monica Boirivant (NIAID)
Ivan J Fuss (NIAID)
Brian L Kelsall (NIAID)


Patent Status:
HHS, Reference No. E-263-1999/0
US, , Patent No. 7,041,296, Issued 09 May 2006


Licensing Status:
Available for licensing


Portfolios:
Internal Medicine - Therapeutics
Rare Diseases



For Additional Information Please Contact:
Patrick McCue Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: McCuepat@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220


Ref No: 2135

Updated: 07/2010